Refractory angina pectoris carries a favourable prognosis: A three-year follow-up of 150 patients
Authors:
- Andreas RückARAndreas Rück
- Christer SylvénCSChrister Sylvén
- for the EUROINJECT ONE study groupFGfor the EUROINJECT ONE study group
- 1 January 2008
- journal article
- research article
- Published by Taylor & Francis in Scandinavian Cardiovascular Journal
- Vol. 42 (5) , 291-294
Abstract
Objective. To investigate the three-year prognosis in refractory angina pectoris. Patients. Two hundred and forty three patients were screened at six European university hospitals for a gene therapy trial. In 150 patients refractory angina pectoris could be confirmed. Vital status was assessed after a mean of 33 months. Results. At baseline, mean age was 63±9 years and mean LVEF was 52±12%. In 61% there was a history of myocardial infarction and 83% had previously been revascularised. Mortality was 5.5% at one year and 13.5% at three years. New revascularisation options were found in 9.5% of the 243 screened patients at baseline coronary angiography. Additionally, in 6% of the trial patients the protocol-specified angiogram after three months revealed new significant stenosis, which was treated by percutaneous intervention. Conclusions. Annual mortality in refractory angina pectoris seems higher than in stable angina pectoris in general, but substantially lower than after myocardial infarction. The “refractoriness” of these patients should be re-evaluated regularly, as new revascularisation options often occur.Keywords
This publication has 15 references indexed in Scilit:
- Favourable long term prognosis in stable angina pectoris: an extended follow up of the angina prognosis study in Stockholm (APSIS)Heart, 2006
- Organization of Myocardial Activation During Ventricular Fibrillation After Myocardial InfarctionCirculation, 2005
- Direct intramyocardial plasmid vascular endothelial growth factor-A165gene therapy in patients with stable severe angina pectorisJACC, 2005
- Transmyocardial revascularization: 5-year follow-up of a prospective, randomized multicenter trialThe Annals of Thoracic Surgery, 2004
- The VIVA TrialCirculation, 2003
- The problem of chronic refractory angina. Report from the ESC Joint Study Group on the Treatment of Refractory AnginaEuropean Heart Journal, 2002
- Pharmacological Treatment of Coronary Artery Disease With Recombinant Fibroblast Growth Factor-2Circulation, 2002
- Clinical outcome of a cohort of patients eligible for therapeutic angiogenesis or transmyocardial revascularizationAmerican Heart Journal, 2001
- Percutaneous transmyocardial laser revascularisation for severe angina: the PACIFIC randomised trialThe Lancet, 2000
- Transmyocardial laser revascularisation compared with continued medical therapy for treatment of refractory angina pectoris: a prospective randomised trialThe Lancet, 1999